- Aegis starts Evoke Pharma (EVOK) at Buy with a $60 target (that represents upside of ~636%).
- Analyst Raghuram Selvaraju likes the regulatory chances for EVK-001 (intranasal metoclopramide).
- "Since the compound in question is already approved for the same indication in which Evoke is aiming to test it, this program seems a low-risk proposition," Selvaraju says.
- Shares +54% premarket
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs